Security Agreement

Recorded: 2008-12-22 Received: 2008-12-22 Pages: 38

Assignor

GTC BIOTHERAPEUTICS, INC.

Executed: 2008-12-19

Assignee

LFB BIOTECHNOLOGIES S.A.S.U.

3, AVENUE DES TROPIQUES, LES ULIS, COURTABOEUF, FRX, 91940, FRANCE

Covered Properties (17)

ERYTHROPOIETIN ANALOG-IgG FUSION PROTEINS

Application: 12/050,569 →

A non-human transgenic mammal expressing a human FcRn on its mammary gland cells and expressing a transgenic protein-human Fc-domain fusion

Application: 11/788,775 →

Antibodies with enhanced antibody-dependent cellular cytotoxicity activity, methods of their production and use

Application: 11/586,431 →

Clarification of Transgenic Milk Using Depth Filtration

Application: 11/355,557 →

Transgenically Produced Antithrombin Iii

Application: 11/284,585 →

Merozoite Surface Protein 1 Lacking Glycosylation Sites

Application: 11/140,676 →

Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection

Application: 11/061,295 →

Compositions and methods for prevention of photoaging

Application: 11/060,041 →

Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof

Application: 11/058,458 →

Methods of protein fractionation using high performance tangential flow filtration

Application: 11/051,216 →

Method of purifying recombinant MSP 1-42 derived from Plasmodium falciparum

Application: 11/007,852 →

Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems

Application: 10/949,975 →

Method for the Production of Fusion Proteins in Transgenic Mammal Milk

Application: 10/933,854 →

Method of using recombinant human antithrombin for neurocognitive disorders

Application: 10/835,836 →

Transgenic and cloned mammals

Application: 10/423,792 →

Erythropoietin Analog-Human Serum Albumin Fusion

Application: 10/081,400 →

Non-Human Transgenic Mammal Comprising a Modified Msp-1 Nucleic Acid

Application: 10/082,018 →